HomeBUSINESS
BUSINESS

Eisai/Biogen’s Alzheimer’s Candidate BAN2401 Disappoints in PII
(Dec.25.2017)

Eisai and Biogen said on December 21 that an independent data monitoring board concluded that one of their Alzheimer’s candidates, BAN2401, failed to meet the primary endpoint at 12 months in a PII trial, but that the study will still continue towards the 18-month endpoint ...
(LOG IN FOR FULL STORY)